Recombinant Plasma Protein Therapeutics Market Size is Projected to Reach USD 17.1 Billion by 2026

​Acumen Research and Consulting has announced the addition of the “Recombinant Plasma Protein Therapeutics Market (By Drug Class: Human C1 Esterase Inhibitor, Recombinant Coagulation Factors; By Cell Line: Chinese Hamster Ovary (CHO) Cell Line, Human Embryonic Kidney (HEK) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Others; By Indication: Hemophilia B, Hemophilia A, Von Willebrand Disease) – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026” report to their offering.

The global Recombinant Plasma Protein Therapeutics Market size is estimated to grow at CAGR above 8.3 % over the forecast time frame 2019-2026 and reach the market value around USD 17.1 billion by 2026.

It is expected that plasma derived protein will be replaced by recombinant plasma products, the number of products being launched will be increased, and demand for new therapies for hemophilia therapy will increase.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1308

Segment Insights
Based on drug class, cell line and indications, the worldwide recombinant plasma protein treatment market has been broken down. Based on the class of the medicines, recombinant clotting and human esterase inhibitors have been classified in the market. A further subsegment of recombinant coagulation factor VIII, recombinant factor IX, recombinant factor VIIa and others was found in the segment of re-combinant coagulatory factors. Recombinant coagulation factor VIII is projected by 2027, due to an increase in homophile A cases worldwide, new product launches and the utilization of recombinant plasma protein therapy for treating Hemophilia A, to make a major portion of the recombinant coagulation factor segment in the market by 2026. The VIIa sub-segment of the recombinant coagulation factor is expected to expand steadily over the forecast period. The Chinese hamster ovary cells (CHO), the baby kidney (BHK), the human embryonic kidney (HEK) cells, and more were categorized as a cell line in the market. Increased utilization of CHO cell lines for the production of therapeutic products is expected to expand to a prominent CAGR in the Chinese cell line (CHO). Based on indication, hemophilia B, hemophilia A, von Willebrand and others were separated from the market.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/recombinant-plasma-protein-therapeutics-market
Regional Outlook
The market will be driven by the rise in the numbers of rare hematology diseases in Asia-Pacific, by the increase in recombinant DNA technology for therapeutic use and by increased R&D spending by companies in pharmaceuticals and biotechnology. In addition, in Japan and China, a growth opportunity is created in the market for recombinant coagulation factors of the third generation. Government and NGOs are currently trying to raise awareness of hemophilia A and B and help the general population understand the cases, diagnoses, and methods of treatment for rare diseases. Currently, with regulatory authorities, countries like China, Japan, Australia and New Zealand have been converted to hemophilia A standard recombinant plasma therapy. 80 percent of patients with bleeding chaos are treated with recombinant coagulation factors according to the Hemophilia Foundation Australia (HFA). Therefore, an increase in recombinant therapies is projected to drive the market during the predicted period for hemophilia treatment.

Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases
Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs
Key Players and Strategies
The Recombinant Plasma Protein Therapeutics market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are Bayer AG, Novo Nordisk A / S, Aptevo Therapeutics, Octapharma, Pharma Group NV, Bioverativ Therapeutics, Inc. (Sanofi),Pfizer Inc., and CSL Limited, Shire (Takeda Pharmaceutical Company Limited) among others.

These companies are able to expand their global market presence through new product launch, purchasing, geographical expansion, collaborations and distribution agreements. Takeda Pharmaceutical Company Limited, a pharmaceutical company based in Japan, was acquired by Shire in January 2019. This acquisition aims to strengthen the geographic presence of Takeda Pharmaceutical Company Limited. Bioverativ Therapeutics Inc., which operates as part of Sanofi Genzyme, has been acquired by Sanofi, the leading pharmaceutical company, in January 2018. Many other players on the market have also taken steps to expand their business in emerging markets. Leading players in the Asia Pacific, such as China, Japan and Australia, also concentrate on increasing their customer base. Market participants are also supporting several campaigns to increase awareness about hematological disorder and the availability and advantages offered by such products of treatments, such as recombinant plasma proteins.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Recombinant Plasma Protein Therapeutics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Recombinant Plasma Protein Therapeutics Market By Drug Class
1.2.2.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.2.2. Global Recombinant Plasma Protein Therapeutics Market Revenue Share By Drug Class in 2017
1.2.2.3. Human C1 Esterase Inhibitor
1.2.2.4. Recombinant Coagulation Factors
1.2.2.5. Others
1.2.3. Recombinant Plasma Protein Therapeutics Market By Cell Line
1.2.3.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison By Cell Line (2015-2026)
1.2.3.2. Chinese Hamster Ovary (CHO) Cell Line
1.2.3.3. Human Embryonic Kidney (HEK) Cell Line
1.2.3.4. Baby Hamster Kidney (BHK) Cell Line
1.2.3.5. Others
1.2.4. Recombinant Plasma Protein Therapeutics Market By Indication
1.2.4.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.4.2. Hemophilia B
1.2.4.3. Hemophilia A
1.2.4.4. Von Willebrand Disease
1.2.4.5. Others
1.2.5. Recombinant Plasma Protein Therapeutics Market by Geography
1.2.5.1. Global Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017

CHAPTER 4. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY DRUG CLASS

4.1. Global Recombinant Plasma Protein Therapeutics Revenue By Drug Class
4.2. Human C1 Esterase Inhibitor
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Recombinant Coagulation Factors
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Other
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY CELL LINE

5.1. Global Recombinant Plasma Protein Therapeutics Revenue By Cell Line
5.2. Chinese Hamster Ovary (CHO) Cell Line
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Human Embryonic Kidney (HEK) Cell Line
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Baby Hamster Kidney (BHK) Cell Line
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY INDICATION

6.1. Global Recombinant Plasma Protein Therapeutics Revenue By Indication
6.2. Hemophilia B
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Hemophilia A
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Von Willebrand Disease
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. NORTH AMERICA RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY

7.1. North America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. North America Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Recombinant Plasma Protein Therapeutics Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
7.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
7.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
7.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
7.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 8. EUROPE RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY

8.1. Europe Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Europe Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
8.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
8.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
8.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
8.6.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
8.7.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY

9.1. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Asia-Pacific Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
9.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
9.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
9.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
9.6.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
9.7.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
9.8.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
9.8.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 10. LATIN AMERICA RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY 

10.1. Latin America Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Latin America Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
10.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
10.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
10.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 11. MIDDLE EAST RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY 

11.1. Middle East Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Middle East Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
11.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
11.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
11.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 12. AFRICA RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY COUNTRY 

12.1. Africa Recombinant Plasma Protein Therapeutics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
12.2. Africa Recombinant Plasma Protein Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
12.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
12.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million)
12.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Octapharma
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Novo Nordisk A / S
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Bayer AG
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Bioverativ Therapeutics, Inc. (Sanofi)
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Aptevo Therapeutics
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Pharma Group NV
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Pfizer Inc.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. CSL Limited
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Shire (Takeda Pharmaceutical Company Limited)
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

Buy this premium research Report @https://www.acumenresearchandconsulting.com/buy-now/0/1308

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157